MRP SynthEquity Nasdaq 100 ETF (SNTQ)
Live price chart, market sentiment, and community perspectives for MRP SynthEquity Nasdaq 100 ETF (CBOE: SNTQ).
Live price chart, market sentiment, and community perspectives for MRP SynthEquity Nasdaq 100 ETF (CBOE: SNTQ).
On our trading desk, we are closely tracking the debut of SNTQ. Managed by Measured Risk Portfolios under Capitol Series Trust and listed on the Cboe BZX Exchange since July 2026, the fund offers an active, non-indexed approach to large-cap equities. However, with an expense ratio sitting at 0.95%, market participants are weighing whether its proprietary weighting scheme can justify the premium over standard passive Nasdaq 100 trackers.
From a risk management standpoint, SNTQ's recent price action around the $24.52 to $25.01 range shows moderate volatility, with a 52-week high of $26.34 and a low of $23.34. Because the fund is actively managed and does not track a standard benchmark index, risk officers must monitor how the proprietary strategy handles broader market drawdowns, especially given the lack of multi-year historical backtesting data.
When evaluating SNTQ for quantitative portfolios, our team noted the absence of standardized Morningstar ratings and third-party analyst coverage due to its July 2026 inception. Analysts conducting due diligence need to reference the direct SEC Form 497 and 497K filings via Capitol Series Trust to properly understand the fund's mechanics, fee structures, and operational parameters through Ultimus Fund Solutions.
From a macro asset allocation perspective, SNTQ's mandate to seek long-term capital appreciation while generating income streams via dividend distributions appeals to specific equity mandates. Nevertheless, the 0.95% fee hurdle means the active management team must consistently outperform traditional broad-based large-cap peers to net out positive alpha for end investors.
Looking at current fund flows and sentiment, SNTQ's average daily volume sits around 52,506 shares, though recent sessions have varied. Institutional interest appears cautious as market participants wait for more definitive performance history across different market cycles before committing larger allocations to Measured Risk Portfolios' active strategy.
Explore plasma cleansing, somatic organ swaps, and BCI.